Phase III Trial Confirms ORR in Previously Treated Patients who Received Opdivo October 20, 2016Vol.39 No.09
Yervoy Improved OS in Fully Resected Stage III Patients from Phase III Study October 20, 2016Vol.39 No.09
Phase III Tecentriq Study Shows Better Survival vs. Chemo Regardless of PD-L1 Status October 20, 2016Vol.39 No.09
Conversation with The Cancer Letter Davidson Moves to Seattle Cancer Consortium October 14, 2016Vol.42 No.38By Paul Goldberg
FreeGuest Editorial Goodman: Too Many PD-1 Trials for Adults, Too Few for Children October 14, 2016Vol.42 No.38By Nancy Goodman
Conversation with The Cancer LetterFree Perspectives on Clinical Development of PD-1 Drugs October 07, 2016Vol.42 No.37
